Subscribe
Share
Share
Embed
Today's hip edition covers four diverse studies examining complex arthroplasty scenarios, surgical approach optimization, pharmaceutical interventions, and fracture fixation biomechanics. We explore outcomes in the challenging population of LVAD recipients undergoing joint replacement, compare thirteen different surgical approaches for total hip arthroplasty, examine five-year follow-up data on denosumab efficacy, and review optimal screw placement strategies for femoral neck fractures.
OrthoDigest is a fully AI-generated daily podcast by Joint Venture Orthopaedics — from automated research discovery and manuscript selection to script writing, voice production, and multilingual translation. Every step of the pipeline is powered by artificial intelligence, making it one of the first fully autonomous medical podcasts. Each episode covers six open-access, peer-reviewed manuscripts on a rotating subspecialty schedule — hip, knee, shoulder & elbow, hand & wrist, foot & ankle, spine, trauma, sports medicine, pediatrics, and oncology. Every study discussed is freely available, with links in the episode notes. Whether you're a surgeon, resident, researcher, or allied health professional, OrthoDigest keeps you current in about 20 minutes a day.
Welcome to OrthoDigest, your daily podcast of orthopaedic literature summaries, brought to you by Joint Venture Orthopaedics. Today is Monday, so we are covering hip. We have four open-access studies for you today, spanning arthroplasty in complex cardiac patients, surgical approach comparisons, denosumab efficacy, and femoral neck fixation biomechanics. As always, links to every manuscript are in the episode description — all are open access. Let's get started.
Our first study is a retrospective observational study by Turan and colleagues, published in the European Journal of Orthopaedic Surgery and Traumatology. This work addresses a challenging clinical scenario that's becoming increasingly common as more patients receive left ventricular assist devices as either bridge to transplant or destination therapy.
The authors leveraged their institutional database to identify patients with HeartMate three LVADs who underwent hip or knee arthroplasty between October two thousand fifteen and June two thousand twenty-four. They found six patients who met criteria and reviewed demographic, clinical, imaging, pharmacologic, and hemodynamic data to assess the feasibility and safety of joint replacement in this high-risk population.
The cohort was notably high-risk with a mean age of sixty-seven point four years, mean BMI of thirty-one point eight, and mean Charlson Comorbidity Index of seven. All six patients were ASA class four. Mean operative time was one hundred twenty-five minutes with estimated blood loss averaging four hundred fifty milliliters. The procedures required substantial healthcare resources, with mean hospital length of stay reaching thirteen days compared to the typical one to three days for routine arthroplasty.
At mean follow-up of thirty-nine and a half months, the survival rate was sixty-seven percent, with thirty-three percent mortality. Importantly, thirty-day readmission occurred in thirty-three percent of patients, and fifty percent developed LVAD-related infections during follow-up. Blood transfusion was required in thirty-three percent, and seventeen percent underwent revision surgery.
So what can you do differently? If you're considering arthroplasty in LVAD patients, this data suggests the procedures are technically feasible but require extensive multidisciplinary coordination and significantly increased healthcare resources. The authors note that meticulous perioperative care by a dedicated multidisciplinary team is necessary to improve safety in select HeartMate three LVAD patients. Given the thirty-three percent mortality rate, careful consideration of expected postoperative longevity and quality of life is essential when evaluating these patients for elective procedures.
The authors acknowledge several important limitations including the small sample size that precludes definitive conclusions, lack of a comparator group of arthroplasty patients without LVADs, and inability to report complications in relation to patient characteristics due to low event rates.
Shifting to surgical technique, our next study is a systematic review and network meta-analysis by Wang and colleagues from BMC Musculoskeletal Disorders. This comprehensive analysis sought to compare the early clinical efficacy and safety of different surgical approaches in total hip arthroplasty.
The authors conducted a frequentist framework network meta-analysis of randomized controlled trials from inception through July two thousand twenty-five, ultimately including eighty-five RCTs encompassing six thousand five hundred seventy-five patients. They compared thirteen different surgical approaches across multiple outcome domains including functional recovery, surgical efficiency, and safety parameters.
The analysis revealed that no single approach demonstrated universal superiority across all measured outcomes. Instead, different approaches showed varying probabilities of advantage depending on the specific outcome examined. For early postoperative Harris Hip Score, the minimally invasive anterolateral approach had the highest probability of achieving the best results with a surface under the cumulative ranking curve value of eighty-eight point seven percent. For medium-to-long-term Harris Hip Score, the modified direct anterior approach ranked highest with a SUCRA value of ninety-seven point eight percent.
When examining surgical efficiency, the minimally invasive posterolateral approach had the highest probability of achieving the shortest operative time with a SUCRA value of ninety-eight point four percent, while also showing an eighty-two point four percent SUCRA value for the smallest postoperative creatine kinase increase. The minimally invasive anterolateral approach demonstrated the highest SUCRA value for blood loss control at ninety point nine percent.
For functional recovery outcomes, the direct anterior approach had the highest SUCRA value for walking speed recovery at ninety-one point eight percent, while the SuperPath approach showed a ninety-five point four percent SUCRA value for physical component summary scores. Regarding safety, the direct lateral approach had the highest SUCRA value for lowest complication risk at ninety-two point nine percent.
So what can you do differently? This data suggests that approach selection should be individualized based on your specific priorities for each patient and your surgical expertise. If you're prioritizing rapid functional recovery, consider the direct anterior approach for walking speed or the SuperPath for overall physical function. If operative efficiency is paramount, the minimally invasive posterolateral approach may offer advantages. For blood loss control, the minimally invasive anterolateral approach showed promise.
As with any network meta-analysis, the usual caveats around heterogeneity and indirect comparisons apply.
Our third study examines the longer-term efficacy of denosumab in preserving bone density after total hip arthroplasty. Sköld and colleagues published this exploratory five-year follow-up of a prospective, randomized, double-blind, placebo-controlled phase two trial in Acta Orthopaedica.
The original trial enrolled non-osteoporotic patients with unilateral hip osteoarthritis receiving uncemented total hip arthroplasty between August two thousand twelve and January two thousand fifteen. Participants received either two subcutaneous doses of denosumab sixty milligrams or placebo, administered one to three days postoperatively and again at six months. Of the sixty-four participants originally randomized, fifty-four participants representing eighty-four percent were available for clinical and imaging assessment at five years.
The primary outcome was periprosthetic bone mineral density assessed using dual-energy X-ray absorptiometry at sixty months follow-up in both acetabular and femoral regions. The results showed no statistically significant differences in bone mineral density between treatment groups at the sixty-month follow-up. The estimated difference in the sum of all acetabular zones was zero point zero four two grams per centimeter squared with a confidence interval of negative zero point three one to zero point three five and a p-value of zero point eight. Similarly, the estimated difference in the sum of all femoral zones was negative zero point zero six grams per centimeter squared with a confidence interval of negative zero point five five to zero point four three and a p-value of zero point eight.
Secondary outcomes including Harris Hip Score and EQ-5D visual analog scale scores were similar between groups at all time points with no statistically significant differences detected. Regarding implant survival, two early stem revisions due to aseptic loosening were recorded, one in each group, within the first two years after surgery. One case of cup revision in the treatment group occurred due to hip joint instability after three years. Sixty-five percent of patients had heterotopic ossification with Brooker classification one or more at the sixty-month follow-up, with no statistically significant difference between groups.
So what can you do differently? This data suggests that short-term denosumab administration around the time of total hip arthroplasty may not provide sustained benefits for periprosthetic bone preservation in non-osteoporotic patients. While earlier results from this same trial showed promise at two years, the lack of sustained benefit at five years questions the clinical value of this intervention in routine arthroplasty practice. Consider reserving denosumab for patients with established osteoporosis where longer-term treatment is already indicated.
The authors acknowledge extensive limitations including restrictive inclusion criteria with BMI less than thirty-five, age sixty-five or younger, and unilateral osteoarthritis that limit generalizability. They also note the use of bone mineral density as a surrogate outcome rather than direct clinical endpoints, underpowered tertiary outcomes, lack of radiostereometric analysis, and absence of systematic vertebral fracture assessment.
Our final study shifts to fracture fixation with a finite element analysis by Wang and colleagues from BMC Musculoskeletal Disorders examining optimal screw placement in the Biplane double-supported screw fixation technique for femoral neck fractures.
The authors created three finite element analysis models of Pauwels type three femoral neck fractures with different distal screw insertion positions using Biplane double-supported screw fixation technology. Under identical loading conditions, they analyzed displacement of internal fixation and femur, stress distribution, and particularly stress distribution in the subtrochanteric region to assess fracture risk.
The analysis revealed that model b, representing the middle position for distal screw placement, had the lowest peak stress values for both the femur and the internal fixation system. The displacement values of both the femur and internal fixation in this middle position model were close to the minimum observed across all three models. Importantly, there was no statistically significant difference in stress magnitude in the subtrochanteric region among the three models, suggesting that distal screw position within the reasonable range does not significantly increase subtrochanteric fracture risk.
So what can you do differently? When performing Biplane double-supported screw fixation for Pauwels three femoral neck fractures, this modeling data suggests positioning your distal screw in the middle of the acceptable placement range rather than at the extremes. The middle position appears to provide optimal mechanical stability without increasing subtrochanteric fracture risk, potentially improving your fixation construct's biomechanical performance.
As with any finite element analysis, the usual caveats around model assumptions and translation to clinical practice apply.
And that wraps up today's edition of OrthoDigest. We covered arthroplasty outcomes in LVAD patients, surgical approach comparisons for total hip arthroplasty, long-term denosumab efficacy, and femoral neck fixation biomechanics. As always, links to all manuscripts are in the episode description — they are all open access, so please do take a look. Thanks for listening, and we will see you tomorrow for knee.